Abbott Abbokinase Relaunches With Limited Indication, Without Bold Warning
Executive Summary
Abbott Abbokinase labeling carries the more limited indication of pulmonary embolism following re-approval of the thrombolytic Oct. 10
You may also be interested in...
Humira Managed Care Coverage At 95%; Abbott Raises Sales Forecast
Abbott's Humira is being reimbursed by 95% of managed care organizations three months after the launch of the tumor necrosis factor inhibitor for rheumatoid arthritis
Humira Managed Care Coverage At 95%; Abbott Raises Sales Forecast
Abbott's Humira is being reimbursed by 95% of managed care organizations three months after the launch of the tumor necrosis factor inhibitor for rheumatoid arthritis
Abbott Will Outlicense Ketolide Antibiotic, Focus On Quinolone And D2E7
Abbott is seeking to outlicense its ketolide antibiotic ABT-773 in lieu of expanding Phase III development to address class issues